Heart Cells as Treatment for Chagas disease

Vida Pharmacal is focused on addressing emerging and neglected diseases through the development of innovative diagnostic and therapeutic products for both veterinary and human patients. The company is pioneering the first diagnostic test and anti-parasiticide specifically for Chagas disease, which significantly impacts millions of people and dogs across the Americas. This initiative aims to provide new hope for affected individuals, as Chagas disease can lead to severe health complications and social stigma in humans, while previously there were no effective treatments available for dogs.

In addition to Chagas disease, Vida Pharmacal is expanding its pipeline to include diagnostic and therapeutic solutions for other diseases, such as Leishmania in canines and felines. The company is working towards obtaining FDA and USDA approvals for its products, which will include the first FDA/CVM-approved treatment for Chagas disease in pets and the first USDA-approved diagnostic test for identifying the disease in animals. This comprehensive approach underscores Vida Pharmacal's commitment to improving health outcomes for both animals and humans affected by these neglected diseases.

United States

Vida Pharmacal develops, markets, and distributes pharmaceuticals designed to treat Neglected Tropical Diseases (NTDs) in veterinary and human patients. Founded in 2017, the company has developed the world’s first treatment for Chagas disease in canines. Vida Pharmacal is headquartered in Spring Branch, Texas.

Vida Pharmacal

Company Details